Intellectual property law

Tauriga Sciences Inc. to Report Important and Material Progress in the Development of its Pharmaceutical Grade Version of Tauri-Gum

Friday, June 5, 2020 - 3:49pm

On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum.This patent application, filed with the United States Patent & Trademark Office (U.S.P.T.O.

Key Points: 
  • On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum.This patent application, filed with the United States Patent & Trademark Office (U.S.P.T.O.
  • Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.
  • The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).
  • On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum.

NICE Actimize X-Sight Marketplace Boosts Efficiency for AML Investigations with Free Services Addressing COVID-19 Challenges

Friday, June 5, 2020 - 11:30am

NICE Actimize, a NICE business (Nasdaq: NICE) and leader in Autonomous Financial Crime Management, today announced that two new X-Sight Marketplace partners are offering a range of free tools and services designed to boost operational efficiency of AML investigations during the onslaught of COVID-19 related demands.

Key Points: 
  • NICE Actimize, a NICE business (Nasdaq: NICE) and leader in Autonomous Financial Crime Management, today announced that two new X-Sight Marketplace partners are offering a range of free tools and services designed to boost operational efficiency of AML investigations during the onslaught of COVID-19 related demands.
  • We look forward to working with the NICE Actimize Marketplace team to deliver exceptional support during this challenging period.
  • Our network of qualified CAMS certified AML specialists look forward to partnering with NICE Actimize and supporting its customers through its advanced Marketplace ecosystem.
  • Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners.

Polsinelli and UnitedLex Launch Unique Partnership Offering Companies Competitive Advantage Through State-of-the-Art IP Management

Friday, June 5, 2020 - 8:00am

Am Law 100 firm Polsinelli and leading technology and legal services company UnitedLex today announced a unique partnership to help businesses gain competitive advantage through state-of-the-art investment and management of intellectual property assets.

Key Points: 
  • Am Law 100 firm Polsinelli and leading technology and legal services company UnitedLex today announced a unique partnership to help businesses gain competitive advantage through state-of-the-art investment and management of intellectual property assets.
  • Monetization and management of intangible intellectual assets create new value for companiesoften in ways traditional tangible assets cannot.
  • The Polsinelli and UnitedLex solution combines the patent experience of a traditional leading law firm with the cutting-edge technology of a legal services company.
  • This offering builds on the unique partnership between these two leading firms announced earlier this year.

Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements

Thursday, June 4, 2020 - 9:05pm

The Staffs determination followed the Companys submission of its compliance plan for the Staffs consideration on May 26, 2020.

Key Points: 
  • The Staffs determination followed the Companys submission of its compliance plan for the Staffs consideration on May 26, 2020.
  • Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.
  • Macrilen is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales.
  • Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

Code42 Pledges Support for Racial Justice, Equity and Inclusion

Thursday, June 4, 2020 - 2:30pm

At Code42, we are heartbroken over another senseless death of an unarmed person of color at the hands of law enforcement.

Key Points: 
  • At Code42, we are heartbroken over another senseless death of an unarmed person of color at the hands of law enforcement.
  • Hire an expert in inclusion to counsel us on how to make our culture more inclusive for historically oppressed people.
  • Raise additional funds through the Code42 Foundation to support the immediate needs of the Black community in Minneapolis as the city is rebuilt.
  • Code42 and the Code42 logo are registered trademarks or trademarks of Code42 Software, Inc. in the United States and/or other countries.

Open Source Software to Drive Telecom's Innovation Agenda by 2025

Thursday, June 4, 2020 - 9:30am

On the other hand, open source is characterized by an agile approach that moves faster.

Key Points: 
  • On the other hand, open source is characterized by an agile approach that moves faster.
  • "Though CSPs are at different timeslots in their digitalization journey, they should collectively propel the open source agenda forward.
  • A close collaboration between standard bodies and open source communities is a step in that direction," says Don Alusha, Senior Analyst at ABI Research.
  • For example, CSPs like Orange and Bell Canada have created internal open source groups in a bid to become more well versed in interacting with community-developed software.

Open Source Software to Drive Telecom's Innovation Agenda by 2025

Thursday, June 4, 2020 - 9:30am

On the other hand, open source is characterized by an agile approach that moves faster.

Key Points: 
  • On the other hand, open source is characterized by an agile approach that moves faster.
  • "Though CSPs are at different timeslots in their digitalization journey, they should collectively propel the open source agenda forward.
  • A close collaboration between standard bodies and open source communities is a step in that direction," says Don Alusha, Senior Analyst at ABI Research.
  • For example, CSPs like Orange and Bell Canada have created internal open source groups in a bid to become more well versed in interacting with community-developed software.

Roya Ghafele leads OxFirst to Award as 'Best Intellectual Property Valuation Firm'

Wednesday, June 3, 2020 - 1:39pm

Under the leadership of Dr Roya Ghafele OxFirst has been for the third time in a row awarded the prestigious prize as Best IP Valuation Firm in the UK by the Global 100 Award.

Key Points: 
  • Under the leadership of Dr Roya Ghafele OxFirst has been for the third time in a row awarded the prestigious prize as Best IP Valuation Firm in the UK by the Global 100 Award.
  • This award underlines the importance of an economic perspective on intellectual property.
  • It shows that the valuation of IP opens up technology approaches, which are simply not available under a mere legal view, says OxFirst Managing Director Roya Ghafele.
  • At another instance, the OxFirst IP valuation helped structure an acquisition in the area of autonomous vehicles.

Covalon Granted Key Antimicrobial Patents in the United States, Canada, and Europe

Wednesday, June 3, 2020 - 12:30pm

Covalon's Antimicrobial Silicone-based Wound Dressing patent has been granted in the United States by the USPTO, in Canada by the CIPO, and in Europe by the EPO.

Key Points: 
  • Covalon's Antimicrobial Silicone-based Wound Dressing patent has been granted in the United States by the USPTO, in Canada by the CIPO, and in Europe by the EPO.
  • This antimicrobial patent is integral to the Company's CovaClear platform technology and the Company's IV Clear, MediClear PreOp, and SurgiClear products.
  • The USPTO also granted the Company a patent for a Method for the Reduction of Microbial Skin Flora, which protects the Company's novel product MediClear PreOp.
  • IV Clear, MediClear, and SurgiClear are registered trademarks of Covalon Technologies Ltd. in Canada, the United States and the United Kingdom.

Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents

Wednesday, June 3, 2020 - 12:00pm

Regeneron had filed oppositions against the Japanese Bradley patents, but the Japanese Bradley patents were upheld in unappealable decisions by the Japanese Patent Office.

Key Points: 
  • Regeneron had filed oppositions against the Japanese Bradley patents, but the Japanese Bradley patents were upheld in unappealable decisions by the Japanese Patent Office.
  • In September 2019, Regeneron filed requests1 at the US Patent Offices PTAB (Patent Trial & Appeal Board2) seeking Inter Partes Review (IPR) proceedings against 4 of the Bradley US patents.
  • In January 2020, Regeneron filed a further request for the PTAB to instigate IPR proceedings on a 5th Kymab patent4.
  • Regeneron appealed to the Australian Federal Court, but in May 2020 Regeneron agreed to discontinue its appeal and Kymabs Australian patent is now upheld.